

References

1. Abaturov AE. *Zdorov'e rebjonka – Child health* 2009;2(17):120–5.
2. Doncov VI, Krut'ko VN, Mrikaev BM, Uhanov SV. Proceedings of the Institute of Systems Analysis, Russian Academy of Sciences 2006;19:50–69.
3. Lapshina EA, Sudnikovich EJu, Kubyshin VL, Zabrodsckaja SV, Maksimchik JuZ, Zavodnik IB. *Biomedicinskaja himija – Biomed Chem* 2006;5:469–78.
4. Mel'nichenko AA, Orehov AN, Sobenin IA. M.:Lap Lambert, 2013.242 c.
5. Panasenko OM, Gorudko IV, Sokolov AV. *Uspehi biologicheskoy himii – The successes of Biol Chemi* 2013;53:195–244.
6. Pristrom AM, Benhamed M. *Lechebnoe delo – Medicine* 2012;1(23):21–8.
7. Ruleva NJu, Zvjaginceva MA, Dugin SF. *Sovremennye naukoemkie tehnologii – Modern high technologies* 2007;8:11–4.
8. Agner K. Verdoperoxidase A ferment isolated from leucocytes. *Acta Chem Scand* 1941;A2 (suppl.8):1–62.
9. Alipour A, Ribalta J, Njo TL. Trans-vessel gradient of myeloperoxidase in coronary artery disease. *Eur J Clin Invest* 2013;43(9):920–5.
10. Alyasin S, Amin R. Intracellular myeloperoxidas in myocardial infarction. *Shiraz E-Med J* 2005;6.
11. Anogeianaki A, Angelucci D, Cianchetti E. Atherosclerosis: a classic inflammatory disease. *Int J Immunopathol Pharmacol* 2011;24(4):817–25.
12. Balanescu S, Calmac L, Constantinescu D, Marinescu M, Onut R, Dorobantu M. Systemic inflammation and early atheroma formation: are they related? *Maedica (Buchar)* 2010;5(4):292–301.
13. Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, Mc Donald TO, Singh P, Anantharamaiah GM, Chait A, Brunzell J, Geary RL, Oram JF, Heinecke JW. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. *PNAS* 2004;101:13032–7.
14. Brinkman V, Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin? *J Cell Biol* 2012;198(5):773–83.
15. Chen W, Liu N, Qi Y, Zhang Y. Changes of systemic and local myeloperoxidase and tumor necrosis factor- α in rats with myocardial injury induced by hindlimb ischemia-reperfusion. *Nan Fang Yi Ke Da Xue Xue Bao* 2013;33 (5):761–4.
16. Delporte C, Antwerpen P, Vanhamme L, Roumeguère T, Boudjeltia KZ. Low-density Lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies. *Mediators Inflamm* 2013;971579. doi: 10.1155/2013/971579.

17. Dullaart RP, Tietge UJ, Kwakernaak AJ. Alterations in plasma lecithin: cholesterol acyltransferase and myeloperoxidase in acute myocardial infarction. *Atherosclerosis* 2014;234(1):185–92.
18. Getz GS, Reardon CA. Myeloperoxidase-mediated dysfunctional high-density lipoprotein. *Arterioscler Thromb Vasc Biol* 2014;34(4):695–6.
19. Graner M, Tikkanen E, Rimpila O, Tikkanen H, Ripatti S, Lokki M-L. Diagnostic efficacy of myeloperoxidase to identify acute coronary syndrome in subjects with chest pain. *Ann Med* 2013;45:322–7.
20. Hansson M, Olsson I, Nauseef W. Biosynthesis, processing and sorting of human myeloperoxidase. *Arch Biochem Bioph* 2006;445:214–24.
21. Hidesuke K. High-density lipoproteins and the immune system. *J Lipids* 2013. – Published online 10.1155/2013/684903.
22. Huang Y, Wu Z, Riwanto M, Gao Sh, Levison BS, Gu X, Fu X, Wagner MA, Besler Ch, Gerstenecker G, Zhang R, Li X-M, DiDonato AJ, Gogonea V, Wilson Tang WH, Smith JD, Plow EF, Fox PL, Shih DM, Lusic AJ, Fisher EA, DiDonato JA, Landmesser U, Hazen SL. Myeloperoxidase and paraoxonase 1 are high-density lipoprotein-associated proteins mechanistically linked to inflammation, oxidant stress and atherosclerosis. *J Clin Invest* 2013;123 (9):3815–28.
23. Kaya MG, Yalcin R, Okyay K, Poyraz F, Bayraktar N, Pasaoglu H, Boyaci B, Cengel A. Potential role of plasms myeloperoxidase level. *Tex Heart Inst J* 2012;39(4):500–6.
24. Klebanoff SJ. Myeloperoxidase: Friend and foe. *J Leuc Biol* 2005;77:598–62.
25. Kolarova H, Klinke A, Kremserova S, Adam M, Pekarova M, Baldus S, Eiserich JP, Kubala L. Myeloperoxidase induces the priming of platelets. *Free Radic Biol Med.* 2013;61:357–69.
26. Kubala L, Kolarova H, Vitecek J. The potentiation of myeloperoxidase activity by the glycosaminoglycan-dependent binding of myeloperoxidase to proteins of the extracellular matrix. *Biochim Biophys Acta.* 2013;1830(10):4524–36.
27. Macickova T, Pecivova J, Harmatha J, Svitekova K, Nosál R. Effect of stilbene derivative on superoxide generation and enzyme release from human neutrophils in vitro. *Interdiscip Toxicol* 2012;5(2):71–5.
28. Malle E, Marshe G, Panzenboeck U, Sayyler W. Myeloperoxidase – mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins. *Arch Biochem Bioph* 2006;445:245–55.
29. Maugeri N., Rovere-Querini P., Evangelista V, Godino C, Demetrio M, Baldini M, Figini F, Coppi G, Slavich M, Camera M, Bartorelli A, Marenzi G, Campana L, Baldissera E, Sabbadini M-G, Cianflone D, Tremoli E, D’Angelo A, Manfredi AA, Maseri A. An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes. *PLoS* 2012;7(6): e39484.
30. Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals. *J Am Coll Cardiol* 2007;50 (2):159–65.

31. Meuwese MC, Trip MD, Wissen S, van Miert JN, Kastelein JJP, Stroes ESG. Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia. *Atherosclerosis* 2008;197 (2):916–21.
32. Nicholls SJ, Hazen SL. The role of myeloperoxidase in the pathogenesis of coronary artery disease. *Jpn J Infect Dis* 2004;57:21–2.
33. Oemrawsingh RM, Lenderink T, Akkerhuis KM. Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome. *Heart* 2011;97(13):1061–6.
34. O'Flynn J, Dixon KO, Faber K, van Kooten C. Myeloperoxidase directs properdin-mediated complement activation. *J Innate Immun* 2013.
35. Patterson EK, Fraser DD, Capretta A, Potter RF, Cepinskas G. Carbon monoxide-releasing molecule 3 inhibits myeloperoxidase and protects against MPO-induced vascular endothelial cell activation/dysfunction. *Free Radic Biol Med*. 26(70C):167–73.
36. Peluso I, Morabito G, Urban L, Ioannone F, Serafini M. Oxidative stress in atherosclerosis development: the central role of LDL and oxidative burst. *Endocr Metab Immune Disord Drug Targets* 2012;12(4):351–360.
37. Que PG, White JG, Holmes B, Good RA. In vitro bactericidal capacity of human polymorphonuclear leucocytes: diminished activity in chronic granulomatous disease of childhood. *J Clin Invest* 1967;46:668–679.
38. Rees MD, Dang L, Thai T, Owen DM, Malle E, Thomas SR. Targeted subendothelial matrix oxidation by myeloperoxidase triggers myosin II-dependent de-adhesion and alters signaling in endothelial cells. *Free Radic Biol Med* 2012;53(12):2344–2356.
39. Salonen I, Huttunen K, Hirvonen MR. Serum myeloperoxidase is independent of the risk factors of atherosclerosis. *Coron Artery Dis* 2012;23(4):251–8.
40. Winterbourn CC, Vissers M, Kettle AJ. Myeloperoxidase. *Curr Opin Hematol* 2000;7:53–8.
41. Yonezawa K, Morimoto N, Matsui K. Significance of the neutrophil myeloperoxidase index in patients with atherosclerotic diseases. *Kobe J Med Sci* 2013;58(5):128–37.
42. Zheng L, Nukuna B, Brennan M-L, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, Hazen SL. Apolipoprotein A-1 is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. *J Clin Invest* 2004;114:529–41.